For a long time, the cure for diabetes type 1 and type 2 has relied on agonizing insulin shots for patients or insulin infusion via mechanical pumps. Regarding this, experts have been creating artificial pancreatic beta cells with the he…
T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) - Pipeline Review, H2 2018
Summary
T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) pipeline Target constitutes close to 21 molecules. Out of which approximately 12 molecules are developed by companies and remaining by the universities/institutes. The latest report T Cell Surface Glycoprotein CD4 - Pipeline Review, H2 2018, outlays comprehensive information on the T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) - CD4 is a glycoprotein found on the surface of immune cells such as T helper cells, monocytes, macrophages, and dendritic cells. It regulates T-cell activation. It induces the aggregation of lipid rafts. It acts as a receptor for human immunodeficiency virus-1, human Herpes virus 7/HHV-7. It is down regulated by HIV-1 Vpu. The molecules developed by companies in Pre-Registration, Phase III, Phase II, Preclinical and Discovery stages are 1, 1, 1, 6 and 3 respectively.
Similarly, the universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 4 and 4 molecules, respectively. Report covers products from therapy areas Infectious Disease, Immunology, Central Nervous System, Cardiovascular and Gastrointestinal which include indications Human Immunodeficiency Virus (HIV) Infections (AIDS), Systemic Lupus Erythematosus, Autoimmune Disorders, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Encephalitis, Graft Versus Host Disease (GVHD), Inflammatory Bowel Disease, Influenza A Virus, H5N1 Subtype Infections, Malaria, Myocarditis, Psoriasis, Severe Acute Respiratory Syndrome (SARS), Simplexvirus (HSV) Infections, Smallpox and West Nile Virus Infections.
Furthermore, this report also reviews key players involved in T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape for T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4)
- The report reviews T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) targeted therapeutics and enlists all their major and minor projects
- The report assesses T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) targeted therapeutics
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4)Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope